Vistance Networks, Inc. (VISN) · Nov 5, 2026 · Earnings

Vistance Networks earnings hold up, but guidance falls to $180M-$200M

Miss — FY adjusted EBITDA cut to $180M-$200M from $200M-$225M prior guide

Vistance Networks earnings showed resilient Aurora margins and orders, but weaker near-term demand forced a lower 2026 adjusted EBITDA outlook.

Vistance Networks is now largely an Aurora Networks story after divesting RUCKUS and CCS, focused on cable-network upgrades such as DOCSIS 4.0 while dealing with memory-chip costs and delayed customer deployments. Its prior full-year adjusted EBITDA guide was already down to $200 million-$225 million because of memory-chip pressure, so this quarter was less about a fresh turnaround than whether the remaining business could stabilize.

The quarter itself was broadly resilient, not a clean beat. Aurora adjusted EBITDA rose 5% year over year to $56.8 million despite revenue falling 5.3%, and orders increased 41% with backlog up 3% to $410 million. That says the underlying upgrade pipeline is still there, but current shipments remain constrained by timing and component costs. Published Q3 estimates were thin and inconsistent; available estimates clustered around roughly $0.12-$0.15 of adjusted EPS, making the reported $0.23 a beat on that narrow measure, while an available revenue estimate near $350.5 million was above the reported $319.7 million.

MetricQ3 2026Q3 2025Consensus / prior guide
Net sales (Summary of Consolidated Results)$319.7M (-5.4%)$337.8M~$350.5M
Aurora adjusted EBITDA (Summary of Consolidated Results)$56.8M (+5.0%)$54.1M
Adjusted EPS (Reconciliation of GAAP Measures)$0.23$0.06~$0.15
Free cash flow (Free Cash Flow)$(57.7)M$135.0M
FY adjusted EBITDA guide (Outlook Reconciliation)$180M-$200M$200M-$225M prior guide

The important change is the outlook cut. Management now expects full-year adjusted EBITDA of $180 million-$200 million, down from the $200 million-$225 million range given after Q2, explicitly because customer demand is being pushed into 2027. The strong order growth and backlog limit the damage to a demand-collapse story, but the near-term earnings profile is weaker than previously expected.

Cash generation remains the weak spot. The company ended the quarter with $683.1 million of cash, no revolver borrowings and approximately $842 million of liquidity, but operating cash flow and free cash flow were both negative. That balance sheet supports continued investment and capital returns, but the new $100 million buyback authorization is discretionary and comes while the business is consuming cash; it reinforces shareholder-return capacity more than it changes the operating story.

Bottom line: Aurora’s orders and margins show the business is still positioned for longer-term DOCSIS 4.0 demand, but delayed deployments have pushed out near-term growth and forced a lower 2026 profit outlook. The filing is modestly negative because the guidance reset matters more than the quarter’s operational stability.

What to watch next

Customer demand conversion into 2027 deployments

Original filing on SEC EDGAR

More Vistance Networks, Inc. news

Vistance Networks earnings hold up, but guidance falls to $180M-$200M | VISN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.